title: Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD.
abstract: The most effective route of administration of rHuEpo is still a matter of discussion. Prospectively we studied subcutaneous (s.c.) versus intravenous (i.v.) administration in three comparable groups of patients; HD-s.c. (n = 9), HD-i.v. (n = 11), and CAPD-s.c. (n = 9). All the groups initially received 50 units/kg three times weekly. During the first 8 weeks dose adjustments were made only if target haemoglobin exceeded 11.3 g/dl (7 mM). Target haemoglobin was reached after 84 (42-98) days in the i.v. group and 42 (14-77) and 42 (28-56) respectively in the HD-s.c. and CAPD groups. The difference was statistically significant (P less than 0.05). Even the cumulative doses to reach target haemoglobin were significantly less in the two s.c. groups. To maintain haemoglobin at about 11.3 g/dl, weekly doses were as follows: HD-i.v. 125 U/kg (86-168), HD-s.c. 63 U/kg (20-85), and CAPD 72 U/kg (31-100). The total observation time after the target haemoglobin level was reached, was median 130 (114-264) days. The difference between the i.v. group and the two s.c. groups was statistically significant, (P less than 0.05) whereas there was no difference between the s.c. groups. We conclude that s.c. administration of rHuEpo is more effective in induction as well as in maintenance therapy and that s.c. administration is equally efficient in HD and CAPD patients.
authors.affiliation: Department of Nephrology B, Herlev University Hospital, Denmark.
authors.forename: I
authors.initials: I
authors.lastname: Eidemak
authors.forename: M O
authors.initials: MO
authors.lastname: Friedberg
authors.forename: S D
authors.initials: SD
authors.lastname: Ladefoged
authors.forename: H
authors.initials: H
authors.lastname: Løkkegaard
authors.forename: E
authors.initials: E
authors.lastname: Pedersen
authors.forename: M
authors.initials: M
authors.lastname: Skielboe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D006435:Renal Dialysis
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin